HEINE H. HANSEN, M.D.; PER DOMBERNOWSKY, M.D.; MOGENS HANSEN, M.D.; FRED HIRSCH, M.D.
A controlled clinical trial compared three-drug and four-drug combination chemotherapy in 109 patients with advanced small-cell anaplastic carcinoma of the lung. The combination of vincristine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), cyclophosphamide, and methotrexate was significantly superior to the combination of the last three drugs alone with regard to median survival (230 versus 176 days) (P < 0.01) and to duration of response (186 versus 112 days) (P < 0.01). Objective response occurred in 78% and 75%, respectively. No significant difference in these values was observed in the comparison of the three subtypes of small-cell anaplastic carcinoma using the World Health Organization's classification.
HANSEN HH, DOMBERNOWSKY P, HANSEN M, HIRSCH F. Chemotherapy of Advanced Small-Cell Anaplastic Carcinoma: Superiority of a Four-Drug Combination to a Three-Drug Combination. Ann Intern Med. ;89:177–181. doi: 10.7326/0003-4819-89-2-177
Download citation file:
Published: Ann Intern Med. 1978;89(2):177-181.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use